Cyber attack hits Merck results, Keytruda notches new milestone

(Reuters) - Merck & Co on Friday said quarterly sales of its Keytruda cancer immunotherapy exceeded $1 billion for the first time, but the cost of a cyber attack that temporarily crippled manufacturing and declines in off-patent products caused overall revenue to fall.